Patents by Inventor DEVAN NADUTHAMBI

DEVAN NADUTHAMBI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PD-1/PD-L1 inhibitors
    Patent number: 12590062
    Abstract: Compounds according to formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.
    Type: Grant
    Filed: November 13, 2020
    Date of Patent: March 31, 2026
    Assignee: Gilead Sciences, Inc.
    Inventors: Evangelos Aktoudianakis, Todd Appleby, Aesop Cho, Zhimin Du, Michael Graupe, Juan A. Guerrero, Salman Y. Jabri, Lateshkumar Thakorlal Lad, Paulo A. Machicao Tello, Jonathan William Medley, Samuel E. Metobo, Prasenjit Kumar Mukherjee, Devan Naduthambi, Gregory Notte, Eric Q. Parkhill, Barton W. Phillips, Scott Preston Simonovich, Neil H. Squires, Chandrasekar Venkataramani, Peiyuan Wang, William J. Watkins, Jie Xu, Kin Shing Yang, Christopher Allen Ziebenhaus
  • Phospholipid compounds and uses thereof
    Patent number: 12473314
    Abstract: Compounds and methods of using said compounds, singly or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
    Type: Grant
    Filed: June 9, 2023
    Date of Patent: November 18, 2025
    Assignee: Gilead Sciences, Inc.
    Inventors: Scott E. Lazerwith, Jonathan William Medley, Philip A. Morganelli, Devan Naduthambi, Thomas P. Stratton, Peiyuan Wang
  • SARS-COV2 MAIN PROTEASE INHIBITORS
    Publication number: 20250296936
    Abstract: The present disclosure relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
    Type: Application
    Filed: February 5, 2025
    Publication date: September 25, 2025
    Inventors: Stephen E. Ammann, Eda Y. Canales, Xinpei Cai, Weng K. Chang, Henok H. Kinfe, Devan Naduthambi, Kevin X. Rodriguez, Scott D. Schroeder, Christopher J. Swank
  • Sars-cov2 main protease inhibitors
    Patent number: 12410183
    Abstract: The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
    Type: Grant
    Filed: June 14, 2024
    Date of Patent: September 9, 2025
    Assignee: Gilead Sciences, Inc.
    Inventors: Stephen E. Ammann, Xinpei Cai, Eda Y. Canales, Weng K. Chang, Gregory F. Chin, Henok H. Kinfe, Scott E. Lazerwith, Jessica L McKinley, Michael R. Mish, Devan Naduthambi, Jason K. Perry, Kevin X Rodriguez, Scott D. Schroeder, Christopher J. Swank, Joshua J. Van Veldhuizen
  • SARS-COV2 MAIN PROTEASE INHIBITORS
    Publication number: 20250276979
    Abstract: The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
    Type: Application
    Filed: February 6, 2025
    Publication date: September 4, 2025
    Inventors: Stephen Ammann, Eda Canales, Weng Chang, Gregory Chin, Henok Kinfe, Devan Naduthambi, Kevin Rodriguez
  • PD-1/PD-L1 INHIBITORS
    Publication number: 20250270195
    Abstract: Compounds of Formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.
    Type: Application
    Filed: May 13, 2025
    Publication date: August 28, 2025
    Inventors: Evangelos Aktoudianakis, Aesop Cho, Zhimin Du, Michael Graupe, Lateshkumar Thakorlal Lad, Paulo A. Machicao Tello, Jonathan William Medley, Samuel E. Metobo, Prasenjit Kumar Mukherjee, Devan Naduthambi, Eric Q. Parkhill, Barton W. Phillips, Scott Preston Simonovich, Neil H. Squires, Peiyuan Wang, William J. Wathins, Jie Xu, Kin Shing Yang, Christopher Allen Ziebenhaus
  • PD-1/Pd-L1 inhibitors
    Patent number: 12338233
    Abstract: Compounds of Formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.
    Type: Grant
    Filed: December 1, 2022
    Date of Patent: June 24, 2025
    Assignee: Gilead Sciences, Inc.
    Inventors: Evangelos Aktoudianakis, Aesop Cho, Zhimin Du, Michael Graupe, Lateshkumar Thakorlal Lad, Paulo A. Machicao Tello, Jonathan William Medley, Samuel E. Metobo, Prasenjit Kumar Mukherjee, Devan Naduthambi, Eric Q. Parkhill, Barton W. Phillips, Scott Preston Simonovich, Neil H. Squires, Peiyuan Wang, William J. Watkins, Jie Xu, Kin Shing Yang, Christopher Allen Ziebenhaus
  • MCL1 INHIBITORS
    Publication number: 20250197421
    Abstract: The present disclosure generally relates to compounds of Formula (I) and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Application
    Filed: November 6, 2024
    Publication date: June 19, 2025
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, David W. Lin, Jonathan William Medley, Devan Naduthambi, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang, QingMing Zhu
  • SUBSTITUTED PYRIDOTRIAZINE COMPOUNDS AND USES THEREOF
    Publication number: 20250188089
    Abstract: The present disclosure relates generally to certain tricyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.
    Type: Application
    Filed: November 20, 2024
    Publication date: June 12, 2025
    Inventors: Hang Chu, Ana Z. Gonzalez Buenrostro, Hongyan Guo, Xiaochun Han, Anna E. Hurtley, Lan Jiang, Jiayao Li, David W. Lin, Michael L. Mitchell, Devan Naduthambi, Gregg M. Schwarzwalder, Suzanne M. Szewczyk, Matthew J. Von Bargen, Qiaoyin Wu, Hong Yang, Jennifer R. Zhang
  • MCL-1 INHIBITORS
    Publication number: 20250154116
    Abstract: The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Application
    Filed: October 17, 2024
    Publication date: May 15, 2025
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Tae H. Hwang, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, John E. Knox, Scott E. Lazerwith, Xiaofen Li, David W. Lin, Jonathan W. Medley, Michael L. Mitchell, Devan Naduthambi, Zachary Newby, Neil H. Squires, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang
  • PD-1/PD-L1 inhibitors
    Patent number: 12269812
    Abstract: Compounds and methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.
    Type: Grant
    Filed: July 8, 2020
    Date of Patent: April 8, 2025
    Assignee: Gilead Sciences, Inc.
    Inventors: Evangelos Aktoudianakis, Aesop Cho, Michael Graupe, Lateshkumar Thakorlal Lad, Paulo A. Machicao Tello, Jonathan William Medley, Samuel E. Metobo, Devan Naduthambi, Barton W. Phillips, Scott Preston Simonovich, Peiyuan Wang, William J. Watkins, Jie Xu, Kin Shing Yang, Christopher Allen Ziebenhaus
  • SARS-COV2 MAIN PROTEASE INHIBITORS
    Publication number: 20250042915
    Abstract: The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
    Type: Application
    Filed: June 14, 2024
    Publication date: February 6, 2025
    Inventors: Stephen E. Ammann, Xinpei Cai, Eda Y. Canales, Weng K. Chang, Gregory F. Chin, Henok H. Kinfe, Scott E. Lazerwith, Jessica L. McKinley, Michael R. Mish, Devan Naduthambi, Jason K. Perry, Kevin X. Rodriguez, Scott D. Schroeder, Christopher J. Swank, Joshua J. Van Veldhuizen
  • PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME
    Publication number: 20250034182
    Abstract: Phospholipid compounds and methods of using the same, singly or in combination with additional agents, and pharmaceutical formulations of said compounds for the treatment of viral infections are disclosed.
    Type: Application
    Filed: June 21, 2024
    Publication date: January 30, 2025
    Inventors: Byoung-Kwon Chun, Michael O. Clarke, Deeba Ensan, Rao V. Kalla, Richard L. Mackman, Jagadeesh N. Manda, Devan Naduthambi, Dustin S. Siegel
  • MCL1 inhibitors
    Patent number: 12202842
    Abstract: The present disclosure generally relates to compounds of Formula (1) and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Grant
    Filed: March 9, 2023
    Date of Patent: January 21, 2025
    Assignee: Gilead Sciences, Inc.
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, David W. Lin, Jonathan William Medley, Devan Naduthambi, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang, Qingming Zhu
  • Substituted pyridotriazine compounds and uses thereof
    Patent number: 12187734
    Abstract: The present disclosure relates generally to certain tricyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.
    Type: Grant
    Filed: December 22, 2023
    Date of Patent: January 7, 2025
    Assignee: Gilead Sciences, Inc.
    Inventors: Hang Chu, Ana Z. Gonzalez Buenrostro, Hongyan Guo, Xiaochun Han, Anna E. Hurtley, Lan Jiang, Jiayao Li, David W. Lin, Michael L. Mitchell, Devan Naduthambi, Gregg M. Schwarzwalder, Suzanne M. Szewczyk, Matthew J. Von Bargen, Qiaoyin Wu, Hong Yang, Jennifer R. Zhang
  • MCL-1 inhibitors
    Patent number: 12162844
    Abstract: The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Grant
    Filed: March 9, 2023
    Date of Patent: December 10, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Tae H. Hwang, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, John E. Knox, Scott E. Lazerwith, Xiaofen Li, David W. Lin, Jonathan W. Medley, Michael L. Mitchell, Devan Naduthambi, Zachary Newby, Neil H. Squires, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang
  • Phospholipid compounds and methods of making and using the same
    Patent number: 12116380
    Abstract: Phospholipid compounds and methods of using the same, singly or in combination with additional agents, and pharmaceutical formulations of said compounds for the treatment of viral infections are disclosed.
    Type: Grant
    Filed: August 16, 2022
    Date of Patent: October 15, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Byoung-Kwon Chun, Michael O. Clarke, Deeba Ensan, Rao V. Kalla, Richard L Mackman, Jagadeesh N. Manda, Devan Naduthambi, Dustin S. Siegel
  • Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
    Patent number: 12110305
    Abstract: Compounds, compositions, and method useful for treating a viral infection, such as human immunodeficiency virus (HIV) and/or hepatitis B virus (HBV) infection, are disclosed. In particular, prodrugs of phosphonamide nucleotide analogues and methods for their preparation and use as therapeutic or prophylactic agents are disclosed.
    Type: Grant
    Filed: August 5, 2021
    Date of Patent: October 8, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Daniel H. Byun, Byoung-Kwon Chun, Michael O. Clarke, Petr Jansa, Devan Naduthambi, Neil H. Squires
  • PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME
    Publication number: 20240309028
    Abstract: Phospholipid compounds and methods of using the same, singly or in combination with additional agents, and pharmaceutical formulations of said compounds for the treatment of viral infections are disclosed.
    Type: Application
    Filed: February 14, 2024
    Publication date: September 19, 2024
    Inventors: Byoung-Kwon Chun, Deeba Ensan, Rao V. Kalla, Devan Naduthambi, Dustin S. Siegel
  • SARS-COV2 main protease inhibitors
    Patent number: 12091420
    Abstract: The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
    Type: Grant
    Filed: October 3, 2023
    Date of Patent: September 17, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Stephen E. Ammann, Xinpei Cai, Eda Y. Canales, Weng K. Chang, Gregory F. Chin, Henok H. Kinfe, Jessica L. Mckinley, Michael R. Mish, Devan Naduthambi, Jason K. Perry, Kevin X. Rodriguez, Scott D. Schroeder, Christopher J. Swank, Joshua J. Van Veldhuizen